Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Queensland Health
Accenture
Daiichi Sankyo
Merck
Boehringer Ingelheim
Express Scripts
AstraZeneca
Teva
Julphar

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,067,431

« Back to Dashboard

Summary for Patent: 8,067,431
Title:Chemically modified small molecules
Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
Inventor(s): Fishburn; C. Simone (Redwood City, CA), Lechuga-Ballesteros; David (San Jose, CA), Viegas; Tacey (Madison, AL), Kuo; Mei-Chang (Palo Alto, CA), Song; Yuan (Belmont, CA), Gursahani; Hema (Foster City, CA), Leach; Chester (Tijeras, NM)
Assignee: Nektar Therapeutics (San Francisco, CA)
Application Number:12/710,167
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,067,431

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,067,431

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,015,197,470 ➤ Subscribe
7,786,133 Chemically modified small molecules ➤ Subscribe
9,388,104 Chemically modified small molecules ➤ Subscribe
8,034,825 Chemically modified small molecules ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,067,431

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1694363 ➤ Subscribe
Serbia 53279 ➤ Subscribe
Portugal 1694363 ➤ Subscribe
New Zealand 594834 ➤ Subscribe
New Zealand 583573 ➤ Subscribe
New Zealand 548529 ➤ Subscribe
Netherlands 300737 ➤ Subscribe
Luxembourg 92702 ➤ Subscribe
Lithuania C1694363 ➤ Subscribe
South Korea 101168620 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Chubb
Cerilliant
Novartis
McKesson
Moodys
McKinsey
Dow
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot